The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

被引：10

作者：

Lunning, Matthew A. ^{[1
]}

Migliacci, Jocelyn C. ^{[2
]}

Hilden, Patrick ^{[3
]}

Devlin, Sean M. ^{[3
]}

Castro-Malaspina, Hugo ^{[2
,4
]}

Giralt, Sergio ^{[2
,4
]}

Perales, Miguel-Angel ^{[2
,4
]}

Zelenetz, Andrew D. ^{[2
,4
]}

Moskowitz, Craig H. ^{[2
,4
]}

Sauter, Craig S. ^{[2
,4
]}

机构：

[1] Univ Nebraska, Dept Med, Omaha, NE USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA

[4] Weill Cornell Med Coll, Dept Med, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷 / 02期

关键词：

follicular lymphoma; stem cell transplantation; non-Hodgkin lymphoma; STEM-CELL TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; RESPONSE CRITERIA; FREE SURVIVAL; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; DOXORUBICIN; IMPROVES; THERAPY;

D O I：

10.1111/bjh.13947

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Early relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post-rituximab era. No difference in event-free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of <= 12 months (80% and 42% at 3years, P < 0015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.

引用

页码：260 / 264

页数：5

共 15 条

[11] The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT
Robinson, S. P.
Canals, C.
Luang, J. J.
Tilly, H.
Crawley, C.
Cahn, J. Y.
Pohlreich, D.
Le Gouill, S.
Gilleece, M.
Milpied, N.
Attal, M.
Biron, P.
Maury, S.
Rambaldi, A.
Maertens, J.
Capria, S.
Colombat, P.
Montoto, S.
Sureda, A.
[J]. BONE MARROW TRANSPLANTATION, 2013, 48 (11) : 1409 - 1414
[12] Pretransplantation Fluorine-18-Deoxyglucose-Positron Emission Tomography Scan Lacks Prognostic Value in Chemosensitive B Cell Non-Hodgkin Lymphoma Patients Undergoing Nonmyeloablative Allogeneic Stem Cell Transplantation
Sauter, Craig S.
Lechner, Lauren
Scordo, Michael
Zheng, Junting
Devlin, Sean M.
Fleming, Stephen E.
Castro-Malaspina, Hugo
Moskowitz, Craig H.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) : 881 - 903
[13] A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients
Sauter, Craig S.
Barker, Juliet N.
Lechner, Lauren
Zheng, Junting
Devlin, Sean M.
Papadopoulos, Esperanza B.
Perales, Miguel-Angel
Jakubowski, Ann A.
Goldberg, Jenna D.
Koehne, Guenther
Ceberio, Izaskun
Giralt, Sergio
Zelenetz, Andrew D.
Moskowitz, Craig H.
Castro-Malaspina, Hugo
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (03) : 354 - 360
[14] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
Schouten, HC
Qian, W
Kvaloy, S
Porcellini, A
Hagberg, H
Johnsen, HE
Doorduijn, JK
Sydes, MR
Kvalheim, G
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3918 - 3927
[15] Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response
Tomblyn, Marcie R.
Ewell, Marian
Bredeson, Christopher
Kahl, Brad S.
Goodman, Stacey A.
Horowitz, Mary M.
Vose, Julie M.
Negrin, Robert S.
Laport, Ginna G.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (07) : 1051 - 1057

← 1 2 →